Phase 4
Completed N=91
Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels
Source: ClinicalTrials.gov NCT00441480 ↗Enrolled (actual)
91
Serious AEs
0.0%
Results posted
Aug 2009
Primary outcomePrimary: LDL Cholesterol — 159.7; 157.8 mg/dl
Summary
The purpose of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly LDL-cholesterol and TG concentrations in healthy hyperlipidemic subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY LDL Cholesterol |
159.7; 157.8 | — |
| PRIMARY LDL-C |
154.7; 155.1 | — |
| SECONDARY Triglycerides |
193.9; 233.0 | — |
| SECONDARY Triglycerides |
193.9; 233.0 | — |
| SECONDARY Total Cholesterol |
233.8; 236.5 | — |
| SECONDARY Total Cholesterol |
233.8; 236.5 | — |
| SECONDARY HDL Cholesterol |
46.0; 44.2 | — |
| SECONDARY HDL-cholestrol |
46.4; 44.7 | — |
| SECONDARY CRP |
2.47; 4.51 | — |
| SECONDARY CRP |
2.47; 4.51 | — |
| SECONDARY Apolipoprotein B100 |
130.0; 130.3 | — |
| SECONDARY Apolipoprotein B100 |
130.0; 130.3 | — |
| SECONDARY Apolipoprotein A |
128.2; 127.8 | — |
| SECONDARY Apolipoprotein A |
128.2; 127.8 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, >18 years old and ≤ 70 years old, capable and willing to give written informed consent.
- Subject must have hyperlipidemia at the screening visit and at the end of the run-in period, defined as: fasting plasma triglycerides > 150 mg/dl and 130 mg/dl and < 190 mg/dl.
- Fasting plasma glucose (FPG) levels at the screening visit < 110 mg/dl.
- Female patient who is of reproductive potential agree to use acceptable methods of birth control
- Female patient who is currently receiving hormone replacement therapy continuously 12 weeks before visit 1 (on stable dose) and will agree to do so during the study.
Exclusion Criteria
- Receiving medications or supplements known to affect lipid metabolism.
- Uncontrolled hypertension or thyroid disease.
- Consume unusual diets - will be determined at the discretion of the investigator.
- Gained or lost more than 3 kg during the run-in period.
- Patient has history of malignancy ≤ 5 years.
- Patients with clinical ischemic CV disease on treatment
- Consume 200 grams fish x 2 a week.
- Gastrointestinal disease or any disease that the investigator feels would compromise the patient safety or limit his/her successful participation to the study.
- Patient has type 1 or type 2 diabetes mellitus.
- Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
- Patient has had active peptic ulcer disease within 3 months of visit 1.
- Woman patient is pregnant or breast-feeding or expecting to conceive during the study.
- Patient has a history of hypersensitivity or allergy to fish, fish oil, corn oil or soy.
Data sourced from ClinicalTrials.gov (NCT00441480). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.